Neurometrix (NURO) – Analysts’ Weekly Ratings Updates

Neurometrix (NASDAQ: NURO) recently received a number of ratings updates from brokerages and research firms:

  • 4/30/2019 – Neurometrix was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neurometrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. “
  • 4/27/2019 – Neurometrix was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.00 price target on the stock. According to Zacks, “Neurometrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. “
  • 4/26/2019 – Neurometrix was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 4/26/2019 – Neurometrix had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
  • 4/1/2019 – Neurometrix was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

NASDAQ NURO traded down $0.06 during mid-day trading on Thursday, reaching $0.76. 66,932 shares of the stock were exchanged, compared to its average volume of 104,317. Neurometrix Inc has a 1 year low of $0.60 and a 1 year high of $1.77. The company has a market capitalization of $6.97 million, a PE ratio of 5.91 and a beta of 0.55.

Neurometrix (NASDAQ:NURO) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.30. Neurometrix had a net margin of 6.36% and a return on equity of 11.77%. The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.92 million. As a group, equities analysts predict that Neurometrix Inc will post -0.33 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Neurometrix stock. Renaissance Technologies LLC increased its position in shares of Neurometrix Inc (NASDAQ:NURO) by 55.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 213,615 shares of the medical device company’s stock after buying an additional 75,932 shares during the period. Renaissance Technologies LLC owned 2.90% of Neurometrix worth $284,000 as of its most recent filing with the SEC. 13.52% of the stock is currently owned by hedge funds and other institutional investors.

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Recommended Story: Convertible Shares

Receive News & Ratings for Neurometrix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply